3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-22335f0d7ee48d7b.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-22335f0d7ee48d7b.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"Image"]
9:I[5864,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"default"]
2:T6c3,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does PYC do?","acceptedAnswer":{"@type":"Answer","text":"PYC Therapeutics is an Australian clinical-stage biotechnology company developing RNA therapeutics for genetic diseases, particularly inherited retinal diseases like Retinitis Pigmentosa and Leber Congenital Amaurosis, and neurodevelopmental disorders such as Phelan-McDermid Syndrome. They focus on delivering RNA drugs into cells using a proprietary platform to modify disease-causing genes."}},{"@type":"Question","name":"Is PYC a good investment?","acceptedAnswer":{"@type":"Answer","text":"Investing in PYC involves significant opportunities alongside considerable risks, typical for a biotechnology company at its stage. Its potential upside is linked to the successful development and commercialization of its innovative RNA drug pipeline for severe genetic conditions. However, investors must consider the high failure rate of drug development, substantial funding needs, and complex regulatory environment inherent in the biotech sector, making it a speculative investment."}},{"@type":"Question","name":"What drives PYC's share price?","acceptedAnswer":{"@type":"Answer","text":"PYC's share price is primarily driven by progress in its drug development pipeline, including key milestones like positive preclinical data, initiation and progression of clinical trials, and compelling clinical trial results (especially safety and efficacy data). Other significant drivers include securing new intellectual property, strategic partnerships, successful capital raises, and regulatory approvals. General market sentiment towards the biotech sector also plays a role."}}]}6:["ticker","PYC","d"]
0:["3Mm9Bv-HUi1IIQFoM0cpZ",[[["",{"children":["asx",{"children":[["ticker","PYC","d"],{"children":["__PAGE__?{\"ticker\":\"PYC\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","PYC","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Pyc Therapeutics Limited"," (","PYC",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Pyc Therapeutics Limited (ASX: PYC) is an Australian clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics to treat blinding eye diseases and neurodevelopmental disorders. Leveraging its proprietary drug delivery platform, PYC aims to deliver RNA drugs into cells to address previously untreatable genetic conditions, operating primarily out of Australia with global ambitions for its pipeline."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$881M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"PYC"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","PYC Therapeutics is currently advancing several promising RNA therapeutic programs, with lead candidates targeting inherited retinal diseases like Retinitis Pigmentosa type 11 (RP11) and Leber Congenital Amaurosis Type 10 (LCA10), as well as a neurological disorder, Phelan-McDermid Syndrome. As a clinical-stage biotechnology company with an A$881M market capitalization, its valuation is predominantly based on the future potential of its drug pipeline rather than current revenues or profits. Recent performance is typically driven by preclinical data, regulatory submissions, and progress towards clinical trials, reflecting the high-risk, high-reward nature inherent in the sector.",{"children":"PYC Therapeutics is currently advancing several promising RNA therapeutic programs, with lead candidates targeting inherited retinal diseases like Retinitis Pigmentosa type 11 (RP11) and Leber Congenital Amaurosis Type 10 (LCA10), as well as a neurological disorder, Phelan-McDermid Syndrome. As a clinical-stage biotechnology company with an A$881M market capitalization, its valuation is predominantly based on the future potential of its drug pipeline rather than current revenues or profits. Recent performance is typically driven by preclinical data, regulatory submissions, and progress towards clinical trials, reflecting the high-risk, high-reward nature inherent in the sector."}],["$","p","The growth outlook for PYC is intrinsically tied to the successful progression of its drug candidates through clinical development and eventual commercialization. Key upcoming catalysts include the initiation of new clinical trials, the reporting of early-stage clinical data, and potential expansion of its pipeline into new indications or partnerships. The company's strategic direction focuses on validating its RNA delivery platform, advancing its lead programs into later-stage clinical trials, and securing intellectual property to position itself as a leader in gene-modifying therapies for rare diseases.",{"children":"The growth outlook for PYC is intrinsically tied to the successful progression of its drug candidates through clinical development and eventual commercialization. Key upcoming catalysts include the initiation of new clinical trials, the reporting of early-stage clinical data, and potential expansion of its pipeline into new indications or partnerships. The company's strategic direction focuses on validating its RNA delivery platform, advancing its lead programs into later-stage clinical trials, and securing intellectual property to position itself as a leader in gene-modifying therapies for rare diseases."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Successful clinical trial outcomes for lead candidates, demonstrating efficacy and safety for significant unmet medical needs (e.g., RP11, LCA10, Phelan-McDermid Syndrome), leading to increased market confidence and valuation.",{"children":["â€¢ ","Successful clinical trial outcomes for lead candidates, demonstrating efficacy and safety for significant unmet medical needs (e.g., RP11, LCA10, Phelan-McDermid Syndrome), leading to increased market confidence and valuation."]}],["$","li","Validation of its proprietary RNA drug delivery platform through positive preclinical and clinical data, attracting potential strategic partnerships or licensing deals with major pharmaceutical companies.",{"children":["â€¢ ","Validation of its proprietary RNA drug delivery platform through positive preclinical and clinical data, attracting potential strategic partnerships or licensing deals with major pharmaceutical companies."]}],["$","li","Expansion of its pipeline into new therapeutic areas or indications, leveraging its platform technology to create multiple high-value assets and diversify future revenue streams.",{"children":["â€¢ ","Expansion of its pipeline into new therapeutic areas or indications, leveraging its platform technology to create multiple high-value assets and diversify future revenue streams."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Failure of drug candidates in preclinical or clinical trials due to lack of efficacy or unacceptable safety profiles, leading to significant pipeline setbacks and potential impairment of development assets.",{"children":["â€¢ ","Failure of drug candidates in preclinical or clinical trials due to lack of efficacy or unacceptable safety profiles, leading to significant pipeline setbacks and potential impairment of development assets."]}],["$","li","Challenges in securing adequate funding for ongoing research and development activities, potentially leading to dilutive capital raises, delays in drug development, or even program discontinuation.",{"children":["â€¢ ","Challenges in securing adequate funding for ongoing research and development activities, potentially leading to dilutive capital raises, delays in drug development, or even program discontinuation."]}],["$","li","Intense competition from other biotechnology companies developing similar or alternative treatments for the same rare diseases, or unforeseen regulatory hurdles in Australia or globally that delay approvals.",{"children":["â€¢ ","Intense competition from other biotechnology companies developing similar or alternative treatments for the same rare diseases, or unforeseen regulatory hurdles in Australia or globally that delay approvals."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Market Sentiment"}],["$","div",null,{"className":"mt-4 flex items-center gap-3","children":[["$","span",null,{"className":"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400","children":["ðŸŸ¡"," ","Mixed"]}],["$","span",null,{"className":"text-xs text-slate-500","children":["Score: ","","0.00"]}]]}],["$","div",null,{"className":"mt-4","children":[["$","div",null,{"className":"flex justify-between text-[10px] uppercase tracking-widest text-slate-500","children":[["$","span",null,{"children":"Bearish"}],["$","span",null,{"children":"Bullish"}]]}],["$","div",null,{"className":"relative mt-1 h-2 rounded-full bg-ink-900/60","children":[["$","div",null,{"className":"absolute left-1/2 top-0 h-full w-px bg-slate-600"}],["$","div",null,{"className":"absolute top-0 h-full w-2 rounded-full bg-yellow-500","style":{"left":"calc(50% - 4px)"}}]]}]]}],["$","div",null,{"className":"mt-4 flex gap-4 text-xs","children":[["$","span",null,{"className":"text-emerald-400","children":["â–² ",0," bullish"]}],["$","span",null,{"className":"text-red-400","children":["â–¼ ",0," bearish"]}],["$","span",null,{"className":"text-slate-500","children":[6," neutral"]}]]}],["$","p",null,{"className":"mt-1 text-xs text-slate-500","children":["Based on ",6," social post","s"]}],["$","div",null,{"className":"mt-4 space-y-2","children":[["$","p",null,{"className":"text-xs uppercase tracking-widest text-slate-500","children":"Recent mentions"}],[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to PYC Therapeutics Limited"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to PYC Therapeutics Limited"}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to PYC Therapeutics Limited"}]]}]]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Investor Webinar"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"5 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"General"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Completion of Placement and Institutional Entitlement Offer"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"3 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Raise"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Pacific Equities Corporation (PYC) has successfully completed the placement and institutional entitlement offer, raising significant capital for future growth."}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Proposed issue of securities - PYC"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"1 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Notice Under Section708AA(2)(f)"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"1 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","4",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"PYC Capital Raising Presentation"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"1 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Price Sensitive"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"PYC is presenting a capital raising initiative, seeking to provide investors with an opportunity for direct equity participation in the company's growth."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does PYC do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does PYC do?"}],["$","p",null,{"className":"text-slate-400","children":"PYC Therapeutics is an Australian clinical-stage biotechnology company developing RNA therapeutics for genetic diseases, particularly inherited retinal diseases like Retinitis Pigmentosa and Leber Congenital Amaurosis, and neurodevelopmental disorders such as Phelan-McDermid Syndrome. They focus on delivering RNA drugs into cells using a proprietary platform to modify disease-causing genes."}]]}],["$","div","Is PYC a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is PYC a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"Investing in PYC involves significant opportunities alongside considerable risks, typical for a biotechnology company at its stage. Its potential upside is linked to the successful development and commercialization of its innovative RNA drug pipeline for severe genetic conditions. However, investors must consider the high failure rate of drug development, substantial funding needs, and complex regulatory environment inherent in the biotech sector, making it a speculative investment."}]]}],["$","div","What drives PYC's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives PYC's share price?"}],["$","p",null,{"className":"text-slate-400","children":"PYC's share price is primarily driven by progress in its drug development pipeline, including key milestones like positive preclinical data, initiation and progression of clinical trials, and compelling clinical trial results (especially safety and efficacy data). Other significant drivers include securing new intellectual property, strategic partnerships, successful capital raises, and regulatory approvals. General market sentiment towards the biotech sector also plays a role."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","1.50"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["22.5","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$881M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"30/03/2005"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/f5dc3b4b8467221e.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"PYC share price, analysis & company profile - Pyc Therapeutics Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest PYC share price overview, what Pyc Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/PYC/"}],["$","meta","5",{"property":"og:title","content":"PYC share price, analysis & company profile - Pyc Therapeutics Limited"}],["$","meta","6",{"property":"og:description","content":"Latest PYC share price overview, what Pyc Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/PYC/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"PYC share price, analysis & company profile - Pyc Therapeutics Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest PYC share price overview, what Pyc Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
